{"entity":{"id":"savolitinib","kind":"drug","name":"Savolitinib","aka":[],"tldr":"Savolitinib is a Chinese-discovered pill that blocks the MET growth signal, approved in China for lung cancers with a MET exon 14 mutation and being tested worldwide with osimertinib.","summary":"Discovered by Hutchmed in Shanghai and partnered with AstraZeneca since 2011, savolitinib received conditional NMPA approval in June 2021 for MET exon 14 skipping NSCLC after platinum chemotherapy or in patients unfit for it, the first selective MET inhibitor approved in China; full approval and first-line use followed. In EGFR-mutant NSCLC with MET-driven resistance to osimertinib, the SAVANNAH and SACHI trials support the savolitinib plus osimertinib combination, with a Chinese approval of the combination in 2025 and the global SAFFRON phase 3 continuing. Also studied in papillary renal cell carcinoma and MET-amplified gastric cancer.","status":"approved","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Savolitinib","links":[{"label":"Hutchmed: Orpathys","url":"https://www.hutch-med.com/"},{"label":"AstraZeneca and Hutchmed","url":"https://www.astrazeneca.com/media-centre/press-releases.html"},{"label":"NMPA (National Medical Products Administration)","url":"https://www.nmpa.gov.cn"}],"tags":["china"],"related":[],"cancers":["nsclc","rcc","gastric","papillary-rcc","met-altered-nsclc","egfr-mutant-nsclc"],"sections":[],"technologies":["kinase-inhibitors"],"targets":["met","egfr"],"drugs":[],"companies":["hutchmed","astrazeneca"],"institutions":[],"pathways":["ras-mapk"],"terms":[],"trials":["nct05009836","nct05043090","nct04606771","nct03944772","nct03091192","nct03778229","nct05261399","nct05374603"],"people":["su-weiguo"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"brand":"Orpathys","code":"HMPL-504, AZD6094, volitinib","modality":"Small-molecule selective MET TKI","mechanism":"Highly selective ATP-competitive inhibitor of MET kinase, active against MET exon 14 skipping mutations and MET amplification.","approvals":[{"region":"China","year":2021,"indication":"MET exon 14 skipping NSCLC after platinum chemotherapy or unfit for chemotherapy (conditional; later full)"},{"region":"China","year":2025,"indication":"With osimertinib in EGFR-mutant NSCLC with MET amplification after EGFR TKI (SACHI)"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/savolitinib/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"},{"id":"met-altered-nsclc","kind":"cancer","name":"MET exon 14 and MET-amplified non-small-cell lung cancer","route":"/cancers/met-altered-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"papillary-rcc","kind":"cancer","name":"Papillary renal cell carcinoma","route":"/cancers/papillary-rcc/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"},{"id":"pulmonary-sarcomatoid-carcinoma","kind":"cancer","name":"Sarcomatoid carcinoma of the lung","route":"/cancers/pulmonary-sarcomatoid-carcinoma/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"},{"id":"met","kind":"target","name":"MET","route":"/targets/met/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"},{"id":"hutchmed","kind":"company","name":"Hutchmed","route":"/companies/hutchmed/"}],"pathway":[{"id":"nsclc-signalling","kind":"pathway","name":"Non-small cell lung cancer (KEGG map)","route":"/pathways/nsclc-signalling/"},{"id":"proteoglycans-in-cancer","kind":"pathway","name":"Proteoglycans in cancer","route":"/pathways/proteoglycans-in-cancer/"},{"id":"ras-mapk","kind":"pathway","name":"RAS / RAF / MEK / ERK (MAPK)","route":"/pathways/ras-mapk/"},{"id":"renal-cell-carcinoma-signalling","kind":"pathway","name":"Renal cell carcinoma (KEGG map)","route":"/pathways/renal-cell-carcinoma-signalling/"}],"trial":[{"id":"nct04606771","kind":"trial","name":"A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC","route":"/trials/nct04606771/"},{"id":"nct05009836","kind":"trial","name":"Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC","route":"/trials/nct05009836/"},{"id":"nct03778229","kind":"trial","name":"Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib","route":"/trials/nct03778229/"},{"id":"papmet","kind":"trial","name":"PAPMET (SWOG S1500)","route":"/trials/papmet/"},{"id":"nct03944772","kind":"trial","name":"Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)","route":"/trials/nct03944772/"},{"id":"nct05374603","kind":"trial","name":"Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC","route":"/trials/nct05374603/"},{"id":"nct05043090","kind":"trial","name":"Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC","route":"/trials/nct05043090/"},{"id":"nct05261399","kind":"trial","name":"Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment","route":"/trials/nct05261399/"},{"id":"nct03091192","kind":"trial","name":"Savolitinib vs. Sunitinib in MET-driven PRCC.","route":"/trials/nct03091192/"}],"person":[{"id":"su-weiguo","kind":"person","name":"Weiguo Su","route":"/people/su-weiguo/"}],"paper":[{"id":"paper-papmet-pal-lancet-2021","kind":"paper","name":"PAPMET (SWOG 1500): cabozantinib versus sunitinib for metastatic papillary renal cell carcinoma","route":"/key-papers/paper-papmet-pal-lancet-2021/"}],"term":[{"id":"met-exon-14-skipping","kind":"term","name":"MET exon 14 skipping mutation","route":"/terms/met-exon-14-skipping/"}]}}